GM-CSF With Post-Transplant Cyclophosphamide

Summary

Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.

Timeline

Start

2020-05-18

Primary completion

2026-09-18

Completion

2026-09-18

Drugs

Indications